Skip to main content
. Author manuscript; available in PMC: 2022 Apr 27.
Published in final edited form as: J Bone Miner Res. 2015 Jun;30(6):1064–1076. doi: 10.1002/jbmr.2433

Fig. 6.

Fig. 6.

Continuous PTH affects osteoblastic and osteoclastic mRNA markers in a sex-specific manner. (A) Igf-l mRNA bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (B) Alkaline phosphatase (ALP) mRNA bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (C) Osteocalcin (OCN)mRNA bone expressionin diaphysis of long bones (femur and tibia) of16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (D) Receptor activator of NF-κB ligand (RANKL) mRNA bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (E) Osteoprotegerin (OPG) mRNA bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (F) RANKL/OPG mRNA ratio bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice. (G) RANK mRNA bone expression in diaphysis of long bones (femur and tibia) of 16-week-old continuously PTH- and vehicle-infused 0CNIgf1r−/− and control mice (n=8–12). Data are shown as mean ± SE; *p < 0.05.